1. Home
  2. DCTH vs MDXG Comparison

DCTH vs MDXG Comparison

Compare DCTH & MDXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

DCTH

Delcath Systems Inc.

N/A

Current Price

$14.38

Market Cap

578.4M

Sector

Health Care

ML Signal

N/A

Logo MiMedx Group Inc

MDXG

MiMedx Group Inc

N/A

Current Price

$3.15

Market Cap

672.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
DCTH
MDXG
Founded
1988
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
578.4M
672.8M
IPO Year
2015
2007

Fundamental Metrics

Financial Performance
Metric
DCTH
MDXG
Price
$14.38
$3.15
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
5
Target Price
★ $24.00
$7.00
AVG Volume (30 Days)
262.9K
★ 1.6M
Earning Date
11-09-2026
10-28-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 107.53
14.29
EPS
★ 0.04
N/A
Revenue
N/A
★ $418,630,000.00
Revenue This Year
$24.61
N/A
Revenue Next Year
$24.27
$12.42
P/E Ratio
$359.43
★ N/A
Revenue Growth
N/A
★ 19.99
52 Week Low
$8.12
$3.03
52 Week High
$17.42
$7.97

Technical Indicators

Market Signals
Indicator
DCTH
MDXG
Relative Strength Index (RSI) 41.86 21.78
Support Level $13.99 $3.11
Resistance Level $16.51 $3.84
Average True Range (ATR) 0.50 0.26
MACD -0.01 -0.09
Stochastic Oscillator 31.58 1.21

Price Performance

Historical Comparison
DCTH
MDXG

About DCTH Delcath Systems Inc.

Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.

About MDXG MiMedx Group Inc

MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, the company sells allografts for ophthalmic surgery and dental applications through licenses to third parties.

Share on Social Networks: